ABBV-706 vs. SOCA Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Sponsor:

AbbVie

Code:

NCT07365241

Conditions

Small Cell Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ABBV-706

Topotecan

Lurbinectedin

Amrubicin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by AbbVie on 2026-09-01.